Article
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.
Blood - 15 Sept 2006
Baccarani Michele, Saglio Giuseppe, Goldman John, Hochhaus Andreas, Simonsson Bengt, Appelbaum Frederick, Apperley Jane, Cervantes Francisco, Cortes Jorge, Deininger Michael, Gratwohl Alois, Guilhot François, Horowitz Mary, Hughes Timothy, Kantarjian Hagop, Larson Richard, Niederwieser Dietger, Silver Richard, Hehlmann Rudiger
Abstract excerpt
The introduction of imatinib mesylate (IM) has revolutionized the treatment of chronic myeloid leukemia (CML). Although experience is too limited to permit evidence-based evaluation of survival, the available data fully justify critical reassessment of CML management. The panel therefore reviewed treatment of CML since 1998. It confirmed the value of IM (400 mg/day) and of conventional allogeneic hematopoietic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.